Center for Biomolecular and Tissue Engineering Center for Biomolecular and Tissue Engineering
Pratt School of Engineering
Duke University
 HOME > pratt > CBTE    Search Help Login 

Publications of Bruce A Sullenger    :chronological  alphabetical  combined  bibtex listing:

Papers Published

  1. SK Buddai, JM Layzer, G Lu, CP Rusconi, BA Sullenger, DM Monroe, S Krishnaswamy, An anticoagulant RNA aptamer that inhibits proteinase-cofactor interactions within prothrombinase., The Journal of biological chemistry, vol. 285 no. 8 (February, 2010), pp. 5212-23, ISSN 1083-351X [doi]  [abs]
  2. J Wang, TP Wakeman, JD Lathia, AB Hjelmeland, XF Wang, RR White, JN Rich, BA Sullenger, Notch promotes radioresistance of glioma stem cells., Stem cells (Dayton, Ohio), vol. 28 no. 1 (January, 2010), pp. 17-28, ISSN 1549-4918 [doi]  [abs]
  3. J Mi, Y Liu, ZN Rabbani, Z Yang, JH Urban, BA Sullenger, BM Clary, In vivo selection of tumor-targeting RNA motifs., Nature chemical biology, vol. 6 no. 1 (January, 2010), pp. 22-4, ISSN 1552-4469 [doi]  [abs]
  4. SM Nimjee, S Oney, Z Volovyk, KM Bompiani, SB Long, M Hoffman, BA Sullenger, Synergistic effect of aptamers that inhibit exosites 1 and 2 on thrombin., RNA (New York, N.Y.), vol. 15 no. 12 (December, 2009), pp. 2105-11, ISSN 1469-9001 [doi]  [abs]
  5. S Oney, RT Lam, KM Bompiani, CM Blake, G Quick, JD Heidel, JY Liu, BC Mack, ME Davis, KW Leong, BA Sullenger, Development of universal antidotes to control aptamer activity., Nature medicine, vol. 15 no. 10 (October, 2009), pp. 1224-8, ISSN 1546-170X [doi]  [abs]
  6. J Zhou, B Soontornworajit, J Martin, BA Sullenger, E Gilboa, Y Wang, A hybrid DNA aptamer-dendrimer nanomaterial for targeted cell labeling., Macromolecular bioscience, vol. 9 no. 9 (September, 2009), pp. 831-5, ISSN 1616-5195 [doi]  [abs]
  7. CM Blake, BA Sullenger, DA Lawrence, YM Fortenberry, Antimetastatic potential of PAI-1-specific RNA aptamers., Oligonucleotides, vol. 19 no. 2 (June, 2009), pp. 117-28, ISSN 1557-8526 [doi]  [abs]
  8. Y Liu, CT Kuan, J Mi, X Zhang, BM Clary, DD Bigner, BA Sullenger, Aptamers selected against the unglycosylated EGFRvIII ectodomain and delivered intracellularly reduce membrane-bound EGFRvIII and induce apoptosis., Biological chemistry, vol. 390 no. 2 (February, 2009), pp. 137-44, ISSN 1431-6730 [doi]  [abs]
  9. Y Liu, QA Sun, Q Chen, TH Lee, Y Huang, WC Wetsel, GA Michelotti, BA Sullenger, X Zhang, Targeting inhibition of GluR1 Ser845 phosphorylation with an RNA aptamer that blocks AMPA receptor trafficking., Journal of neurochemistry, vol. 108 no. 1 (January, 2009), pp. 147-57, ISSN 1471-4159 [doi]  [abs]
  10. Z Mi, H Guo, MB Russell, Y Liu, BA Sullenger, PC Kuo, RNA aptamer blockade of osteopontin inhibits growth and metastasis of MDA-MB231 breast cancer cells., Molecular therapy : the journal of the American Society of Gene Therapy, vol. 17 no. 1 (January, 2009), pp. 153-61, ISSN 1525-0024 [doi]  [abs]
  11. SB Long, MB Long, RR White, BA Sullenger, Crystal structure of an RNA aptamer bound to thrombin., RNA (New York, N.Y.), vol. 14 no. 12 (December, 2008), pp. 2504-12, ISSN 1469-9001 [doi]  [abs]
  12. J Lee, CM Dollins, D Boczkowski, BA Sullenger, S Nair, Activated B cells modified by electroporation of multiple mRNAs encoding immune stimulatory molecules are comparable to mature dendritic cells in inducing in vitro antigen-specific T-cell responses., Immunology, vol. 125 no. 2 (October, 2008), pp. 229-40, ISSN 1365-2567 [doi]  [abs]
  13. CM Dollins, S Nair, D Boczkowski, J Lee, JM Layzer, E Gilboa, BA Sullenger, Assembling OX40 aptamers on a molecular scaffold to create a receptor-activating aptamer., Chemistry & biology, vol. 15 no. 7 (July, 2008), pp. 675-82, ISSN 1074-5521 [doi]  [abs]
  14. KD Viles, BA Sullenger, Proximity-dependent and proximity-independent trans-splicing in mammalian cells., RNA (New York, N.Y.), vol. 14 no. 6 (June, 2008), pp. 1081-94, ISSN 1469-9001 [doi]  [abs]
  15. CM Dollins, S Nair, BA Sullenger, Aptamers in immunotherapy., Human gene therapy, vol. 19 no. 5 (May, 2008), pp. 443-50, ISSN 1557-7422 [doi]
  16. S Sarraf-Yazdi, J Mi, BJ Moeller, X Niu, RR White, CD Kontos, BA Sullenger, MW Dewhirst, BM Clary, Inhibition of in vivo tumor angiogenesis and growth via systemic delivery of an angiopoietin 2-specific RNA aptamer., The Journal of surgical research, vol. 146 no. 1 (May, 2008), pp. 16-23, ISSN 0022-4804 [doi]  [abs]
  17. J Mi, X Zhang, ZN Rabbani, Y Liu, SK Reddy, Z Su, FK Salahuddin, K Viles, PH Giangrande, MW Dewhirst, BA Sullenger, CD Kontos, BM Clary, RNA aptamer-targeted inhibition of NF-kappa B suppresses non-small cell lung cancer resistance to doxorubicin., Molecular therapy : the journal of the American Society of Gene Therapy, vol. 16 no. 1 (January, 2008), pp. 66-73, ISSN 1525-0024 [doi]  [abs]
  18. SH Hong, JS Jeong, YJ Lee, HI Jung, KS Cho, CM Kim, BS Kwon, BA Sullenger, SW Lee, IH Kim, In vivo reprogramming of hTERT by trans-splicing ribozyme to target tumor cells., Molecular therapy : the journal of the American Society of Gene Therapy, vol. 16 no. 1 (January, 2008), pp. 74-80, ISSN 1525-0024 [doi]  [abs]
  19. RR White, JA Roy, KD Viles, BA Sullenger, CD Kontos, A nuclease-resistant RNA aptamer specifically inhibits angiopoietin-1-mediated Tie2 activation and function., Angiogenesis, vol. 11 no. 4 (2008), pp. 395-401, ISSN 1573-7209 [doi]  [abs]
  20. PH Giangrande, J Zhang, A Tanner, AD Eckhart, RE Rempel, ER Andrechek, JM Layzer, JR Keys, PO Hagen, JR Nevins, WJ Koch, BA Sullenger, Distinct roles of E2F proteins in vascular smooth muscle cell proliferation and intimal hyperplasia., Proceedings of the National Academy of Sciences of the United States of America, vol. 104 no. 32 (August, 2007), pp. 12988-93, ISSN 0027-8424 [doi]  [abs]
  21. J Mi, X Zhang, Y Liu, SK Reddy, ZN Rabbani, BA Sullenger, BM Clary, NF-kappaB inhibition by an adenovirus expressed aptamer sensitizes TNFalpha-induced apoptosis., Biochemical and biophysical research communications, vol. 359 no. 3 (August, 2007), pp. 475-80, ISSN 0006-291X [doi]  [abs]
  22. MN Kierlin-Duncan, BA Sullenger, Using 5'-PTMs to repair mutant beta-globin transcripts., RNA (New York, N.Y.), vol. 13 no. 8 (August, 2007), pp. 1317-27, ISSN 1355-8382 [doi]  [abs]
  23. NS Que-Gewirth, BA Sullenger, Gene therapy progress and prospects: RNA aptamers., Gene therapy, vol. 14 no. 4 (February, 2007), pp. 283-91, ISSN 0969-7128 [doi]  [abs]
  24. S Oney, SM Nimjee, J Layzer, N Que-Gewirth, D Ginsburg, RC Becker, G Arepally, BA Sullenger, Antidote-controlled platelet inhibition targeting von Willebrand factor with aptamers., Oligonucleotides, vol. 17 no. 3 (2007), pp. 265-74, ISSN 1545-4576 [doi]  [abs]
  25. JM Layzer, BA Sullenger, Simultaneous generation of aptamers to multiple gamma-carboxyglutamic acid proteins from a focused aptamer library using DeSELEX and convergent selection., Oligonucleotides, vol. 17 no. 1 (2007), pp. 1-11, ISSN 1545-4576 [doi]  [abs]
  26. SM Nimjee, JR Keys, GA Pitoc, G Quick, CP Rusconi, BA Sullenger, A novel antidote-controlled anticoagulant reduces thrombin generation and inflammation and improves cardiac function in cardiopulmonary bypass surgery., Molecular therapy : the journal of the American Society of Gene Therapy, vol. 14 no. 3 (September, 2006), pp. 408-15, ISSN 1525-0016 [doi]  [abs]
  27. JO McNamara 2nd, ER Andrechek, Y Wang, KD Viles, RE Rempel, E Gilboa, BA Sullenger, PH Giangrande, Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras., Nature biotechnology, vol. 24 no. 8 (August, 2006), pp. 1005-15, ISSN 1087-0156 [doi]  [abs]
  28. J Mi, X Zhang, ZN Rabbani, Y Liu, Z Su, Z Vujaskovic, CD Kontos, BA Sullenger, BM Clary, H1 RNA polymerase III promoter-driven expression of an RNA aptamer leads to high-level inhibition of intracellular protein activity., Nucleic acids research, vol. 34 no. 12 (2006), pp. 3577-84, ISSN 1362-4962 [doi]  [abs]
  29. J Mi, X Zhang, PH Giangrande, JO McNamara 2nd, SM Nimjee, S Sarraf-Yazdi, BA Sullenger, BM Clary, Targeted inhibition of alphavbeta3 integrin with an RNA aptamer impairs endothelial cell growth and survival., Biochemical and biophysical research communications, vol. 338 no. 2 (December, 2005), pp. 956-63, ISSN 0006-291X [doi]  [abs]
  30. JP Jones 3rd, MN Kierlin, RG Coon, J Perutka, AM Lambowitz, BA Sullenger, Retargeting mobile group II introns to repair mutant genes., Molecular therapy : the journal of the American Society of Gene Therapy, vol. 11 no. 5 (May, 2005), pp. 687-94, ISSN 1525-0016 [doi]  [abs]
  31. SM Nimjee, CP Rusconi, RA Harrington, BA Sullenger, The potential of aptamers as anticoagulants., Trends in cardiovascular medicine, vol. 15 no. 1 (January, 2005), pp. 41-5, ISSN 1050-1738 [doi]  [abs]
  32. SM Nimjee, CP Rusconi, BA Sullenger, Aptamers: an emerging class of therapeutics., Annual review of medicine, vol. 56 (2005), pp. 555-83, ISSN 0066-4219 [doi]  [abs]
  33. BA Sullenger, Riboswitches--to kill or save the messenger., The New England journal of medicine, vol. 351 no. 26 (December, 2004), pp. 2759-60, ISSN 1533-4406 [doi]
  34. CP Rusconi, JD Roberts, GA Pitoc, SM Nimjee, RR White, G Quick Jr, E Scardino, WP Fay, BA Sullenger, Antidote-mediated control of an anticoagulant aptamer in vivo., Nature biotechnology, vol. 22 no. 11 (November, 2004), pp. 1423-8, ISSN 1087-0156 [doi]  [abs]
  35. A Potti, CP Rusconi, BA Sullenger, TL Ortel, Regulatable aptamers in medicine: focus on antithrombotic strategies., Expert opinion on biological therapy, vol. 4 no. 10 (October, 2004), pp. 1641-7, ISSN 1744-7682 [doi]  [abs]
  36. KS Shin, BA Sullenger, SW Lee, Ribozyme-mediated induction of apoptosis in human cancer cells by targeted repair of mutant p53 RNA., Molecular therapy : the journal of the American Society of Gene Therapy, vol. 10 no. 2 (August, 2004), pp. 365-72, ISSN 1525-0016 [doi]  [abs]
  37. ML Jeter, LV Ly, YM Fortenberry, HC Whinna, RR White, CP Rusconi, BA Sullenger, FC Church, RNA aptamer to thrombin binds anion-binding exosite-2 and alters protease inhibition by heparin-binding serpins., FEBS letters, vol. 568 no. 1-3 (June, 2004), pp. 10-4, ISSN 0014-5793 [doi]  [abs]
  38. JM Layzer, AP McCaffrey, AK Tanner, Z Huang, MA Kay, BA Sullenger, In vivo activity of nuclease-resistant siRNAs., RNA (New York, N.Y.), vol. 10 no. 5 (May, 2004), pp. 766-71, ISSN 1355-8382  [abs]
  39. SM Nimjee, BA Sullenger, The Sabiston vision of basic science in a department of surgery., Annals of surgery, vol. 238 no. 6 Suppl (December, 2003), pp. S28-32, ISSN 0003-4932
  40. J Byun, N Lan, M Long, BA Sullenger, Efficient and specific repair of sickle beta-globin RNA by trans-splicing ribozymes., RNA (New York, N.Y.), vol. 9 no. 10 (October, 2003), pp. 1254-63, ISSN 1355-8382  [abs]
  41. MB Long, JP Jones 3rd, BA Sullenger, J Byun, Ribozyme-mediated revision of RNA and DNA., The Journal of clinical investigation, vol. 112 no. 3 (August, 2003), pp. 312-8, ISSN 0021-9738 [doi]
  42. BA Sullenger, Targeted genetic repair: an emerging approach to genetic therapy., The Journal of clinical investigation, vol. 112 no. 3 (August, 2003), pp. 310-1, ISSN 0021-9738 [doi]
  43. RR White, S Shan, CP Rusconi, G Shetty, MW Dewhirst, CD Kontos, BA Sullenger, Inhibition of rat corneal angiogenesis by a nuclease-resistant RNA aptamer specific for angiopoietin-2., Proceedings of the National Academy of Sciences of the United States of America, vol. 100 no. 9 (April, 2003), pp. 5028-33, ISSN 0027-8424 [doi]  [abs]
  44. BA Sullenger, RR White, CP Rusconi, Therapeutic aptamers and antidotes: a novel approach to safer drug design., Ernst Schering Research Foundation workshop no. 43 (2003), pp. 217-23, ISSN 0947-6075
  45. CS Rogers, CG Vanoye, BA Sullenger, AL George Jr, Functional repair of a mutant chloride channel using a trans-splicing ribozyme., The Journal of clinical investigation, vol. 110 no. 12 (December, 2002), pp. 1783-9, ISSN 0021-9738 [doi]  [abs]
  46. CP Rusconi, E Scardino, J Layzer, GA Pitoc, TL Ortel, D Monroe, BA Sullenger, RNA aptamers as reversible antagonists of coagulation factor IXa., Nature, vol. 419 no. 6902 (September, 2002), pp. 90-4, ISSN 0028-0836 [doi]  [abs]
  47. BA Sullenger, E Gilboa, Emerging clinical applications of RNA., Nature, vol. 418 no. 6894 (July, 2002), pp. 252-8, ISSN 0028-0836 [doi]  [abs]
  48. RE Martell, JR Nevins, BA Sullenger, Optimizing aptamer activity for gene therapy applications using expression cassette SELEX., Molecular therapy : the journal of the American Society of Gene Therapy, vol. 6 no. 1 (July, 2002), pp. 30-4, ISSN 1525-0016  [abs]
  49. Nimje,S. and Sullenger, B.A.(2002)the Sabiston Vision of Basic Science in a Department of Surgery.  Annals of Surgery, In Press.
  50. Sullenger,B.A., White,R.R. and Rusconi,C.P.(2002)Therapeutic Aptamers and Antidotes: A Novel Approach to Safer Drug Design. In Ernst Schering Research Foundation Symposium Series.
  51. T Watanabe, BA Sullenger, RNA repair: a novel approach to gene therapy., Advanced drug delivery reviews, vol. 44 no. 2-3 (November, 2000), pp. 109-18, ISSN 0169-409X  [abs]
  52. CP Rusconi, A Yeh, HK Lyerly, JH Lawson, BA Sullenger, Blocking the initiation of coagulation by RNA aptamers to factor VIIa., Thrombosis and haemostasis, vol. 84 no. 5 (November, 2000), pp. 841-8, ISSN 0340-6245  [abs]
  53. BA Sullenger, Series introduction: emerging clinical applications of nucleic acids, The Journal of clinical investigation, vol. 106 no. 8 (October, 2000), pp. 921-2, ISSN 1558-8238 [doi]
  54. RR White, BA Sullenger, CP Rusconi, Developing aptamers into therapeutics., The Journal of clinical investigation, vol. 106 no. 8 (October, 2000), pp. 929-34, ISSN 0021-9738 [doi]
  55. N Lan, BL Rooney, SW Lee, RP Howrey, CA Smith, BA Sullenger, Enhancing RNA repair efficiency by combining trans-splicing ribozymes that recognize different accessible sites on a target RNA., Molecular therapy : the journal of the American Society of Gene Therapy, vol. 2 no. 3 (September, 2000), pp. 245-55, ISSN 1525-0016 [doi]  [abs]
  56. T Watanabe, BA Sullenger, Induction of wild-type p53 activity in human cancer cells by ribozymes that repair mutant p53 transcripts., Proceedings of the National Academy of Sciences of the United States of America, vol. 97 no. 15 (July, 2000), pp. 8490-4, ISSN 0027-8424 [doi]  [abs]
  57. MB Long, BA Sullenger, Evaluating group I intron catalytic efficiency in mammalian cells., Molecular and cellular biology, vol. 19 no. 10 (October, 1999), pp. 6479-87, ISSN 0270-7306  [abs]
  58. BA Sullenger, RNA repair as a novel approach to genetic therapy., Gene therapy, vol. 6 no. 4 (April, 1999), pp. 461-2, ISSN 0969-7128 [doi]
  59. PP Zarrinkar, BA Sullenger, Optimizing the substrate specificity of a group I intron ribozyme., Biochemistry, vol. 38 no. 11 (March, 1999), pp. 3426-32, ISSN 0006-2960 [doi]  [abs]
  60. PP Zarrinkar, BA Sullenger, Probing the interplay between the two steps of group I intron splicing: competition of exogenous guanosine with omega G., Biochemistry, vol. 37 no. 51 (December, 1998), pp. 18056-63, ISSN 0006-2960  [abs]
  61. N Lan, RP Howrey, SW Lee, CA Smith, BA Sullenger, Ribozyme-mediated repair of sickle beta-globin mRNAs in erythrocyte precursors., Science (New York, N.Y.), vol. 280 no. 5369 (June, 1998), pp. 1593-6, ISSN 0036-8075  [abs]
  62. JT Jones, BA Sullenger, Evaluating and enhancing ribozyme reaction efficiency in mammalian cells., Nature biotechnology, vol. 15 no. 9 (September, 1997), pp. 902-5, ISSN 1087-0156 [doi]  [abs]
  63. SW Lee, BA Sullenger, Isolation of a nuclease-resistant decoy RNA that can protect human acetylcholine receptors from myasthenic antibodies., Nature biotechnology, vol. 15 no. 1 (January, 1997), pp. 41-5, ISSN 1087-0156 [doi]  [abs]
  64. 2. Jones, J. T. and Sullenger, B. A. (1997). Evaluating and enhancing ribozyme reaction efficiency in mammalian cells. Nature Biotechnology 15, 902-905..
  65. 1. Lee, S.-W. and Sullenger, B. A. (1997). Isolation of a nuclease resistant decoy RNA that can protect human acetylcholine receptors from myasthenic antibodies. Nature Biotechnology, 15, 41-45.
  66. 3. Jones, J. T., Lee, S.-W., and Sullenger, B. A. (1997). Trans-splicing reactions by ribozymes. In Methods in Molecular Biology. Vol. 74: Ribozyme Protocols (ed. Turner, P.), pp. 341-348. 4. Milich, L and Sullenger, B. A. (1997). Ribozymes as tools for the gene therapist. In Concepts in Gene Therapy (eds. Strauss, M. and Barranger, J.A.) pp. 195-227.
  67. 5. Sullenger, B. A. (1997). RNA repair: The next wave of gene therapy. J. NIH Research 9, 37-40.
  68. JT Jones, SW Lee, BA Sullenger, Trans-splicing reactions by ribozymes., Methods in molecular biology (Clifton, N.J.), vol. 74 (1997), pp. 341-8, ISSN 1064-3745 [doi]
  69. J Ishizaki, JR Nevins, BA Sullenger, Inhibition of cell proliferation by an RNA ligand that selectively blocks E2F function., Nature medicine, vol. 2 no. 12 (December, 1996), pp. 1386-9, ISSN 1078-8956  [abs]
  70. BA Sullenger, Ribozyme-mediated repair of RNAs encoding mutant tumor suppressors., Cytokines and molecular therapy, vol. 2 no. 3 (September, 1996), pp. 201-5, ISSN 1355-6568  [abs]
  71. SW Lee, BA Sullenger, Isolation of a nuclease-resistant decoy RNA that selectively blocks autoantibody binding to insulin receptors on human lymphocytes., The Journal of experimental medicine, vol. 184 no. 2 (August, 1996), pp. 315-24, ISSN 0022-1007  [abs]
  72. JT Jones, SW Lee, BA Sullenger, Tagging ribozyme reaction sites to follow trans-splicing in mammalian cells., Nature medicine, vol. 2 no. 6 (June, 1996), pp. 643-8, ISSN 1078-8956  [abs]
  73. Jones, J. T., Lee, S.-W., and Sullenger, B. A.: Trans-splicing reactions by ribozymes. In Press 1996.
  74. 4. Jones, J. T., Lee S.-W., and Sullenger, B. A. (1996). Tagging ribozyme reaction sites to follow trans-splicing in mammalian cells. Nature Medicine 2, 643-648.
  75. Sullenger, B. A.: Ribozyme-mediated repair of RNAs encoding mutant tumor suppressors. In Press 1996.
  76. BA Sullenger, Colocalizing ribozymes with substrate RNAs to increase their efficacy as gene inhibitors., Applied biochemistry and biotechnology, vol. 54 no. 1-3 (December, 1995), pp. 57-61, ISSN 0273-2289  [abs]
  77. BA Sullenger, Revising messages traveling along the cellular information superhighway., Chemistry & biology, vol. 2 no. 5 (May, 1995), pp. 249-53, ISSN 1074-5521  [abs]
  78. JA Doudna, TR Cech, BA Sullenger, Selection of an RNA molecule that mimics a major autoantigenic epitope of human insulin receptor., Proceedings of the National Academy of Sciences of the United States of America, vol. 92 no. 6 (March, 1995), pp. 2355-9, ISSN 0027-8424  [abs]
  79. Smith, C. and Sullenger, B. A.: Aids and HIV infection. In Molecular and Cell Biology of Human Gene Therapeutics. Ed. Dickson, G. Chapman and Hall, London, pp.195-236, 1995.
  80. Sullenger, B. A.: Adapting ribozymes to be gene inhibitors. Applied Biochemistry and Biotechnology 54, 57-61, 1995.
  81. Sullenger, B. A. and Cech, T. R.: RNA repair: a new possibility for gene therapy. The Journal of NIH Research 7, 46-47, 1995.
  82. Cambell, T. B. and Sullenger, B. A.: The use of ribozymes as antiviral agents. Advances in Pharmacology 33. 143-178, 1995.
  83. Sullenger, B. A.: RNA Repair: revising messages traveling along the cellular information superhighway. Chemistry & Biology 2, 249-253, 1995.
  84. C Smith, BA Sullenger, AIDS and HIV infection., Molecular and cell biology of human diseases series, vol. 5 (1995), pp. 195-236, ISSN 1470-0573
  85. TB Campbell, BA Sullenger, Alternative approaches for the application of ribozymes as gene therapies for retroviral infections., Advances in pharmacology (San Diego, Calif.), vol. 33 (1995), pp. 143-78, ISSN 1054-3589
  86. BA Sullenger, TR Cech, Ribozyme-mediated repair of defective mRNA by targeted, trans-splicing., Nature, vol. 371 no. 6498 (October, 1994), pp. 619-22, ISSN 0028-0836 [doi]  [abs]
  87. Sullenger, B. A. and Cech, T. R.: Ribozyme-mediated repair of defective mRNA by targeted trans-splicing. Nature 317, 619-622, 1994.
  88. BA Sullenger, TR Cech, Tethering ribozymes to a retroviral packaging signal for destruction of viral RNA., Science (New York, N.Y.), vol. 262 no. 5139 (December, 1993), pp. 1566-9, ISSN 0036-8075  [abs]
  89. Sullenger, B. A. and Cech, T. R.: Tethering ribozymes to a retroviral packaging signal for destruction of viral RNA. Science 262, 1566-1569, 1993.
  90. 2. Sullenger, B. A. and Cech, T. R. (1993). Tethering ribozymes to a retroviral packaging signal for destruction of viral RNA. Science 262, 1566-1569.
  91. TC Lee, BA Sullenger, HF Gallardo, GE Ungers, E Gilboa, Overexpression of RRE-derived sequences inhibits HIV-1 replication in CEM cells., The New biologist, vol. 4 no. 1 (January, 1992), pp. 66-74, ISSN 1043-4674  [abs]
  92. BA Sullenger, HF Gallardo, GE Ungers, E Gilboa, Analysis of trans-acting response decoy RNA-mediated inhibition of human immunodeficiency virus type 1 transactivation., Journal of virology, vol. 65 no. 12 (December, 1991), pp. 6811-6, ISSN 0022-538X  [abs]
  93. BA Sullenger, TC Lee, CA Smith, GE Ungers, E Gilboa, Expression of chimeric tRNA-driven antisense transcripts renders NIH 3T3 cells highly resistant to Moloney murine leukemia virus replication., Molecular and cellular biology, vol. 10 no. 12 (December, 1990), pp. 6512-23, ISSN 0270-7306  [abs]
  94. BA Sullenger, HF Gallardo, GE Ungers, E Gilboa, Overexpression of TAR sequences renders cells resistant to human immunodeficiency virus replication., Cell, vol. 63 no. 3 (November, 1990), pp. 601-8, ISSN 0092-8674  [abs]
  95. 1. Sullenger, B. A., Gallardo, H. F., Ungers, G. E., and Gilboa, E. (1990). Overexpression of TAR sequences renders cells resistant to human immunodeficiency virus replication. Cell 63, 601-608.
  96. PA Hantzopoulos, BA Sullenger, G Ungers, E Gilboa, Improved gene expression upon transfer of the adenosine deaminase minigene outside the transcriptional unit of a retroviral vector., Proceedings of the National Academy of Sciences of the United States of America, vol. 86 no. 10 (May, 1989), pp. 3519-23, ISSN 0027-8424  [abs]
Duke University * Pratt * CBTE * Reload * Login
x